Our study found that personalized treatment for HF patients according to their genotypes in VKORC1 and UGT1A6 gene polymorphisms could help clinicians to identify recommended doses of antiplatelet (aspirin) and anticoagulant (warfarin) drugs. The gene discussed is VKORC1; the disease is hydrops fetalis.